

FERIVA 21 7- ascorbic acid, zinc glycinate, cyanocobalamin, ferrous asparto glycinate, folic acids and succinic acid tablet
Avion Pharmaceuticals, LLC

FeRiva 21/7
Rx Only
Dietary Supplement

DESCRIPTION

FeRiva 21/7[®] tablets for oral administration is a 28-day iron supplement regimen that consists of 21 red, oval-shaped iron tablets and 7 purple, oval-shaped placebo tablets. Each red, oval-shaped iron tablet is debossed with “21” and “7” separated by a line in the middle on the top-side of the tablet and blank on the other side. Each purple, oval shaped placebo tablet is blank on both sides of the tablet.

Supplement Facts		% Daily Value	% Daily Value for Pregnant & Lactating Women
Serving Size: 1 tablet			
Each Red Iron Tablet Contains:			
Vitamin C (as Ascorbic Acid)	175 mg	292%	292%
Zinc (as Zinc Bisglycinate)	10 mg	67%	67%
Vitamin B ₁₂ (as Cyanocobalamin)	12 mcg	200%	150%
Iron (as Ferrrous Asparto Glycinate) Sumalate [®]	75 mg	417%	417%
Folate (as ((6S)-N5-methyltetrahydrofolic acid calcium salt (molar equivalent to 600 mcg of folic acid) and folic acid, USP 400 mcg)	1 mg	250%	125%
Succinic Acid	150 mg	†	†
† Daily Value (DV) not established.			
PURPLE PLACEBO TABLETS do not contain ANY vitamins, minerals or other dietary ingredients. Please see OTHER INGREDIENTS section below for the listing of the inert ingredients.			

OTHER INGREDIENTS (RED IRON TABLETS)

Croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose, silicon dioxide, and stearic acid. Coating contains: FD&C Red #40, HMPC, titanium dioxide and triacetin.

OTHER INGREDIENTS (PURPLE PLACEBO TABLETS)

Croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose, silicon dioxide, and stearic acid. Coating contains: HMPC, titanium dioxide, triacetin, and FD&C Red #3, FD&C Blue #1.

INDICATIONS

FeRiva 21/7[®] is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency.

CONTRAINDICATIONS

FeRiva 21/7® is contraindicated in patients with a known hypersensitivity to any of the ingredients. Hemochromatosis and hemosiderosis are contraindicated to iron therapy.

WARNING

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. **KEEP THIS PRODUCT OUT OF REACH OF CHILDREN.** In case of accidental overdose, call a doctor or poison control center immediately.

PRECAUTIONS

Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folic acid in doses above 1.0 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress. While prescribing this nutritional supplement for pregnant women, nursing mothers or for women prior to conception, their medical condition and other drugs, herbs and/or supplements consumption should be considered.

ADVERSE REACTIONS

Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

DOSAGE AND ADMINISTRATION

Usual dosage is one tablet daily with or without food or as prescribed by your healthcare provider. The FeRiva 21/7® Tablets blister pack supplies a 28-day course of iron therapy that consists of 21 red iron tablets and 7 purple placebo tablets. Take 1 red iron tablet daily for 21 days, followed by 1 purple placebo tablet daily for 7 days. After 28 tablets have been taken a new course may be started if prescribed.

HOW SUPPLIED

FeRiva 21/7® tablets blister pack (75854-318-28) contains 21 red iron tablets and 7 purple placebo tablets. The listed product number is not a National Drug Code. Instead Avion Pharmaceuticals has assigned a product code formatted according to standard industry practice to meet the formatting requirements of pharmacy and health insurance computer systems.

Keep out of reach of children. Store between 20°- 25°C (68°- 77°F).

Sumalate® is a registered trademark of Albion Laboratories, Inc., covered by one or more claims of U.S. Patent Nos. 6,716,814, 8,007,846, and 8,425,956.

Avion Pharmaceuticals, LLC
Alpharetta, GA 30022
1-888-61-AVION L-0057 Rev. 1219-02

PRINCIPAL DISPLAY PANEL - 28 tablet container label

75854-318-28 RX ONLY

FeRiva 21/7

IRON SUPPLEMENT

Unique, Innovative Iron Supplementation System

• Enhanced GI Tolerability • Improved Absorption • Easy-to-swallow tablets

Once Daily

28-DAY IRON SUPPLEMENT REGIMEN

Avion

PHARMACEUTICALS

FeRiva 21/7
28-DAY IRON SUPPLEMENT REGIMEN
Once Daily

● Enhanced GI Tolerability ● Improved Absorption ● Easy-to-swallow tablets

Unique, Innovative Iron Supplementation System

IRON SUPPLEMENT

FeRiva 21/7

75854-318-28

FeRiva 21/7

Rx ONLY

Is Only Dietary Supplement

DESCRIPTION: FeRiva 21/7® tablets for oral administration is a 28-day iron supplement regimen that consists of 21 red, oval-shaped iron tablets and 7 purple, oval-shaped placebo tablets. Each red, oval-shaped iron tablet is debossed with "21" and "7" separated by line in the middle on the top-side of the tablet and blank on the other side. Each purple, oval shaped placebo tablet is blank on both sides of the tablet.

INDICATIONS: FeRiva 21/7® is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency.

CONTRAINDICATIONS: FeRiva 21/7® is contraindicated in patients with a known hypersensitivity to any of the ingredients. Hemochromatosis and hemosiderosis are contraindicated to iron therapy.

WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. **Keep this product out of reach of children.** In case of accidental overdose, call a doctor or poison control center immediately.

PRECAUTIONS: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folic acid in doses above 1.0 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress. While prescribing this nutritional supplement for pregnant women, nursing mothers or for women prior to conception, their medical condition and other drugs, herbs and/or supplements consumption should be considered.

ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

DOSEAGE AND ADMINISTRATION: Usual dosage is one tablet daily with or without food or as prescribed by your healthcare provider. The FeRiva 21/7® tablets blister pack supplies a 28-day course of iron therapy that consists of 21 red iron tablets and 7 purple placebo tablets. Take 1 red iron tablet daily for 21 days, followed by 1 purple placebo tablet daily for 7 days. After 28 tablets have been taken a new course may be started if prescribed.

HOW SUPPLIED: FeRiva 21/7® tablets blister pack (75854-318-28) contains 21 red iron tablets and 7 purple placebo tablets. The listed product number is not a National Drug Code. Instead Avion Pharmaceuticals has assigned a product code formatted according to standard industry practice to meet the formatting requirements of pharmacy and health insurance computer systems. Keep out of reach of children. Store between 20°-25°C (68°-77°F). Sunatara® is a registered trademark of Albion Laboratories, Inc., covered by one or more claims of U.S. Patent Nos. 5,516,025, 6,716,814, 8,007,846, and 8,425,958.

Supplement Facts	% Daily Value for Nutrient	% Daily Value for Percent Daily Requirements	
Each Red Iron Tablet Contains:			
Vitamin C (as Ascorbic Acid)	175 mg	292%	292%
Zinc (as Zinc Glycinate)	10 mg	67%	67%
Vitamin B ₁₂ (as Cyanocobalamin)	12 mcg	200%	150%
Iron (as Ferrous Asparto Glycinate) Succinate*	75 mg	417%	417%
Folate	1700 mcg DFE	4250%	280%
* (as (S)-4S-methyltetrahydrofolic acid calcium salt (equivalent to 600 mcg of folic acid) and folic acid, USP 400 mcg)			
Succinic Acid	150 mg	+	+

OTHER INGREDIENTS (RED IRON TABLETS): Croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose, silicon dioxide and stearic acid. Coating contains: FD&C Red #40, HPMC, Titanium Dioxide and Talc.

OTHER INGREDIENTS (PURPLE PLACEBO TABLETS): Croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose, silicon dioxide and stearic acid. Coating contains: HPMC, Titanium Dioxide, Talc and FD&C Red #3 and FD&C Blue #1.

Avion
PHARMACEUTICALS
Albion Pharmaceuticals, LLC
Apotheca, GA 30005 1-866-61-AVION
L-0057 Rev 12/19-02

FeRiva 21/7

3 75854 31828 2

THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.

FERIVA 21 7

ascorbic acid, zinc glycinate, cyanocobalamin, ferrous asparto glycinate, folic acids and succinic acid tablet

Product Information

Product Type	DIETARY SUPPLEMENT	Item Code (Source)	NHRIC:75854-318
Route of Administration	ORAL		

Active Ingredient/Active Moiety				
	Ingredient Name	Basis of Strength	Strength	
	ASCORBIC ACID (UNII: PQ6CK8PD0R) (ASCORBIC ACID - UNII:PQ6CK8PD0R)	ASCORBIC ACID	175 mg	
	ZINC GLYCINATE (UNII: 681VJX72FE) (ZINC CATION - UNII:13S1S8SF37)	ZINC GLYCINATE	10 mg	
	CYANOCOBALAMIN (UNII: P6YC3EG204) (CYANOCOBALAMIN - UNII:P6YC3EG204)	CYANOCOBALAMIN	12 ug	
	FERROUS ASPARTO GLYCINATE (UNII: H7426RGB3L) (FERROUS CATION - UNII:GW895810WR)	FERROUS CATION	75 mg	
	FOLIC ACID (UNII: 935E97BOY8) (FOLIC ACID - UNII:935E97BOY8)	FOLIC ACID	1 mg	
	SUCCINIC ACID (UNII: AB6MNQ6J6L) (SUCCINIC ACID - UNII:AB6MNQ6J6L)	SUCCINIC ACID	150 mg	
Inactive Ingredients				
	Ingredient Name	Strength		
	ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)			
	MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)			
	STEARIC ACID (UNII: 4ELV7Z65AP)			
	SILICON DIOXIDE (UNII: ETJ7Z6XBU4)			
	MAGNESIUM STEARATE (UNII: 70097M6I30)			
	CROSCARMELOSE SODIUM (UNII: M28OL1HH48)			
	HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)			
	TITANIUM DIOXIDE (UNII: 15FIX9V2JP)			
	TRIACETIN (UNII: XHX3C3X673)			
	FD&C RED NO. 3 (UNII: PN2ZH5LOQY)			
	FD&C RED NO. 40 (UNII: WZB9127XOA)			
	FD&C BLUE NO. 1 (UNII: HBR47K3TBD)			
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NHRIC:75854-318-28	28 in 1 CARTON		
1		1 in 1 BLISTER PACK		
Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
DIETARY SUPPLEMENT		10/20/2014		

Supplement Facts	
Serving Size :	Serving per Container :
Amount Per Serving	% Daily Value
color	
color	
scoring	1
shape	

size (solid drugs)	7 mm
imprint	

Labeler - Avion Pharmaceuticals, LLC (040348516)

Establishment

Name	Address	ID/FEI	Business Operations
Avion Pharmaceuticals, LLC		040348516	manufacture(75854-318)

Revised: 1/2021

Avion Pharmaceuticals, LLC